Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528196 | 0.93 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL16247191 | 0.93 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| Hydrogen Sulfide SCHEMBL21332270 | 0.92 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL21332271 | 0.91 | MAPT (0.48) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL18700363 | 0.88 | KMT2A (0.43) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL16456689 | 0.88 | CXCR1 (0.51) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL14028790 | 0.85 | KDM4E (0.45) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL20471580 | 0.85 | KMT2A (0.41) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL18700356 | 0.85 | KDM4E (0.47) | ALDH1A1MAPTKDM4EKMT2AHPGD | |
| SCHEMBL16541405 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032172-B1 | LEPTOMYCIN DERIVATIVES | SANOFI SA (FR) | 2012-06-06 | — | — | EP | claimed |
| US-10654873-B2 | Cytotoxic agents and conjugates thereof | POLYTHERICS LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190202839-A1 | Novel Cytotoxic Agents And Conjugates Thereof | ABZENA (CAMBRIDGE) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-20170360952-A1 | BIOMOLECULE CONJUGATES | CELGENE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| WO-2017176648-A1 | TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-10-12 | — | — | WO | disclosed |
| EP-1542723-B1 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN INC (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2032172-A2 | LEPTOMYCIN DERIVATIVES | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | disclosed |
| EP-1542723-A4 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN INC (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007144709-A2 | LEPTOMYCIN DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-12-21 | — | — | WO | disclosed |
| US-6913748-B2 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1542723-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | Immunogen, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004016801-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654873-B2 | Cytotoxic agents and conjugates thereof | CD2BP2, DDB1, DCLRE1A | ALDH1A1 1528/4885MAPT 4353/4885KDM4E 4204/4885 |
| US-20170360952-A1 | BIOMOLECULE CONJUGATES | DNPEP, NAPA, NCL | ALDH1A1 1533/4885MAPT 3052/4885KDM4E 4806/4885 |
| US-20190202839-A1 | Novel Cytotoxic Agents And Conjugates Thereof | CD2BP2, DDB1, DCLRE1A | ALDH1A1 1838/4885MAPT 4584/4885KDM4E 4121/4885 |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | CD44, ABCG2, EPCAM | ALDH1A1 1402/4885MAPT 2302/4885KDM4E 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.